• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
april@madhedgefundtrader.com

December 27, 2023

Jacque's Post

 

(THE HOUSING CRISIS IN YOUR FUTURE IS BROUGHT TO YOU BY CLIMATE CHANGE)

December 27, 2023

 

Hello everyone,

Most of us know about the changing climate. But few of us realize the implications of these changes on housing over the next 30 years and beyond.

We know about interest rates and the cost of housing, but what about the relationship between climate and the cost of housing?

 

 

It’s another crisis, which is going to spread its tentacles worldwide. No country will escape.

Dave Burt, CEO of investment research firm DeltaTerra Capital believes an overlooked and unpriced climate risk could see a repeat of a financial crisis in housing, albeit on a smaller scale in relation to the 2008 crisis. But still, it’s a damaging real threat to exposed communities.

Dave Burt was among the few skeptics who recognized the housing market was on the brink of collapse in 2007. He helped two of the protagonists of Michael Lewis’ bestselling book “The Big Short” bet against the mortgage market in the lead-up to the 2008 global financial crisis. As it turned out, they were right and were estimated to have made millions.

Now here in 2023, Burt believes an overlooked climate risk could see history repeating itself.
Burt argues that DeltaTerra Capital’s research suggests that 20% of U.S. homes have “meaningful exposure” to a mispricing issue because of flood risk. If realized, he warned the fallout could resemble the extraordinary correction seen during the global financial crisis.

Even though he says that it could be a quarter the size and magnitude of the GFC, it still would be very damaging to exposed communities. Burt argues that there are cracks starting to appear in terms of the cost of insurance. Think about Hurricane Ian in Florida, for instance. The recovery here was an issue, particularly because this storm surge exposed a flood insurance nightmare for homeowners. We can also think about the people in Lismore, Australia, where the residents have endured about three major floods in 18 months. Some residents have left, never to return. Others have offered their house to the market for around 200k. The only way people will be able to live in these areas again is if the houses are built on stilts, if the community is relocated, or if major feats of engineering are undertaken to protect the town.

 

 

I would argue that most people do not lose a lot of sleep over the climate crisis in relation to their portfolio. But a recent study has warned the U.S. housing market could be overvalued by around $200 billion due to unpriced flood risks.

This analysis was published in mid-February in the journal Nature Climate Change. Authored by researchers from the Environmental Defence Fund, the First Street Foundation, and the U.S. Federal Reserve, among others, the study modeled property-level changes in flood risk across the U.S. over the next three decades and warned that low-income households were particularly vulnerable to home value devaluation.

 

 

Jeremy Porter, head of climate implications at the First Street Foundation said it is a huge concern because climate risk is not being priced into the housing market. He goes on to say that the costs now or the valuation of homes don’t consider the realization of that actual flood risk, and that’s not taking into account that there seems to be a huge amount of overvaluation attached to properties across the country.

Insufficient climate risk information when purchasing a home poses a significant financial hazard as households could lose a large proportion of their property value overnight.
Eventually, Burt argues, there is going to be some sort of national tipping point where there is some type of bubble that bursts.

Presently, the study said that nearly 15 million U.S. properties face a 1% annual likelihood of flooding, with expected annual damages to residential properties forecast to exceed $32 billion.
In addition, the research also warned the increasing frequency and severity of flooding amid the deepening climate emergency could see the number of U.S. properties exposed to flooding increase by 11% and average annual losses jump by at least 26% by 2050.

The vacuum in climate-related information when purchasing property needs to be addressed. People need to understand what the climate-related costs are going to look like and rethink their property location if they cannot meet those costs.

 

 

Lower-income property owners are most at risk and this, in turn, has the potential to widen the wealth gap in the U.S. and exacerbate inequality.

How will local government tax revenues be affected?

They could be hit quite badly, as the total for municipalities typically relies heavily on property taxes. Having that tied to a physical asset that is exposed to climate change introduces a lot of risk to the stability of that revenue stream according to DeltaTerra Capital research.

This is not just a domestic issue. It is a problem for countries worldwide. And it morphs into a humanitarian crisis when you start looking at the issue through a global lens.

Munich Re, the world’s largest reinsurance company, observed steep economic losses in 2022 as the climate crisis drove more extreme weather events, such as Hurricane Ian in the U.S. and apocalyptic flooding in Pakistan. Reinsurance refers to insurance for insurance companies.

It estimated that these losses amounted to $270 billion last year, of which around $120 billion was covered by insurance. The insured loss total continues a trend of high losses in recent years.
Someone must pay in the end. Whether insured or uninsured, it becomes an increasing economic burden.

 

 

So, before you purchase your next property consider the climate cost also.

Be safe and enjoy time with family and/or friends.

Cheers,

Jacque

“The world is reaching the tipping point beyond which climate change may become irreversible. If this happens, we risk denying present and future generations the right to a healthy and sustainable planet – the whole of humanity stands to lose.” - Kofi Annan, Former Secretary-General of the UN.

 

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-27 12:00:292023-12-27 10:59:15December 27, 2023
april@madhedgefundtrader.com

Trade Alert - (UNG) December 27, 2023 - BUY LEAPS

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-27 11:34:302023-12-27 11:44:03Trade Alert - (UNG) December 27, 2023 - BUY LEAPS
april@madhedgefundtrader.com

December 27, 2023

Diary, Newsletter, Summary

Global Market Comments
December 27, 2023
Fiat Lux

SPECIAL ISSUE ABOUT THE FAR FUTURE

Featured Trade:
(PEAKING INTO THE FUTURE WITH RAY KURZWEIL),
(GOOG), (INTC), (AAPL), (TXN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-27 09:04:372023-12-27 10:47:35December 27, 2023
april@madhedgefundtrader.com

December 26, 2023

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
December 26, 2023
Fiat Lux

Featured Trade:

(A MARATHON, NOT A SPRINT)

(AMGN), (ABBV), (DNA), (PFE), (RHHBY), (GILD), (NVO)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-26 12:02:312023-12-26 12:35:02December 26, 2023
april@madhedgefundtrader.com

A Marathon, Not A Sprint

Biotech Letter

Navigating the stock market, where fortunes are made and lost faster than a New York minute, can be as exhilarating as it is nerve-wracking.

And when you're hunting for that quick win, that short-term stock buy that'll make your year, you realize you're playing a game where even the big guns like Warren Buffett don't always have the magic crystal ball.

But let's pivot a bit. What about when you're not sweating under a cash crunch — when you can afford to play the long game?

That's when you shift your sights to those long-term compounders, the kind that churn out robust returns on capital like a well-oiled machine. Here, initial valuations play second fiddle to the long-term prospects.

This is where Amgen (AMGN) struts onto the stage. It's not just any old player in the biotechnology and healthcare arena; it's a front-runner with a knack for keeping its coffers brimming and its profitability soaring.

In terms of therapeutic innovation, Amgen is a leader in the fields of oncology, inflammation, neurology, and pulmonary diseases. Their biosimilar practice is also on the rise, churning out replicas of blockbuster drugs like AbbVie’s (ABBV) Humira and Genentech’s (DNA) Herceptin.

Essentially, investing in Amgen is like finding a gold mine in your backyard – and then realizing there's oil under there, too.

Now, let's talk numbers because that's where the rubber meets the road. Amgen's moat-worthy drug franchises make it as solid as a rock for those seeking stability in their cash flows, especially when economic clouds are gathering.

And in the healthcare segment, it's akin to building your house on a rock – it withstands economic storms.

Amgen is known for its industry-leading profitability, flashing its A+ grade like a badge of honor. Their 11% return on total capital and a jaw-dropping 134% return on equity? That's not just good; it's like winning the financial Olympics.

Over the last decade, Amgen's total return of 218% didn't just outdo the S&P 500; it left peers like Pfizer (PFE), Roche (RHHBY), and Gilead (GILD) in the dust. Sure, AbbVie is still ahead, but that's mostly thanks to their Humira magic.

Fast forward to the present, and Amgen's showing no signs of slowing down.

Their total revenue shot up by 4% YoY to $6.9 billion in the third quarter, courtesy of a surge in volumes across their star products. We're talking double-digit growth in BLINCYTO, EVENITY, Repatha, and Nplate. This is like watching a relay race where every runner is Usain Bolt.

Peeking into the future, Amgen's pipeline is a treasure trove of potential.

The company has six first-in-class oncology assets and three FDA Breakthrough Therapy designations. Mirroring Novo Nordisk's (NVO) success with Ozempic, Amgen’s wrapped up Phase 2 studies for their obesity contender, Maridebart cafraglutide.

But here's where it gets even more interesting. Amgen's leap into multi-specific drugs, particularly with tumor treatment AMG 193, is like stepping into a sci-fi novel – it's groundbreaking, it's futuristic, and it just might revolutionize drug delivery.

Let's not forget the FDA's priority review of tarlatamab for small-cell lung cancer. This isn't just good news; it's a potential game-changer, a sign that Amgen might just be first across the finish line in this high-stakes race.

Of course, the recent acquisition of Horizon Therapeutics adds another feather to Amgen's cap, expanding its rare disease portfolio. The incoming drugs from this deal, including Tavneos, Tepezza, KRYSTEXXA, and UPLIZNA, are in the early stages of their lifecycle, making them ripe for growth.

However, every silver lining has a cloud. The integration of Horizon Therapeutics carries its own set of risks, and Amgen's legacy drugs like Enbrel and Otezla face the ticking clock of declining sales.

We also can’t gloss over the elephant in the room – Amgen's ballooning long-term debt, expected to hit a whopping $65 billion by year-end. The recent downgrade of Amgen's credit rating to BBB is like a cautious tap on the shoulder, a reminder to tread carefully.

But don't let that dampen your spirits. Amgen's 3.3% dividend yield is as solid as it comes, with management showing a vote of confidence with a 5.6% raise for the upcoming Q1 2024 payout.

The company's history of rewarding shareholders through share buybacks – a 19% reduction in share count over five years is nothing to scoff at either.

So, where does that leave Amgen's valuation? At a current price of $275 and a forward PE of 14.8, it's not exactly a bargain basement, but it's far from sky-high. It's in that sweet spot where quality meets value.

For long-term investors who value stability and growth, consider adding Amgen to your portfolio playbook.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-26 12:00:292023-12-26 12:34:42A Marathon, Not A Sprint
april@madhedgefundtrader.com

AI Alert - (UNG) December 26, 2023 - BUY LEAPS

Mad Hedge AI

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-26 11:45:042023-12-26 12:16:21AI Alert - (UNG) December 26, 2023 - BUY LEAPS
april@madhedgefundtrader.com

December 26, 2023

Diary, Newsletter, Summary

Global Market Comments
December 26, 2023
Fiat Lux

Featured Trade:

(THE NEXT COMMODITY SUPERCYCLE HAS ALREADY STARTED),
(COPX), (GLD), (FCX), (BHP), (RIO), (SIL),
(PPLT), (PALL), (GOLD), (ECH), (EWZ), (IDX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-26 09:04:172023-12-26 12:19:20December 26, 2023
april@madhedgefundtrader.com

December 22, 2023

Tech Letter

Mad Hedge Technology Letter
December 22, 2023
Fiat Lux

Featured Trade:

(THE FUTURE IS HERE)
(NO CODE)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-22 14:04:102023-12-22 11:20:34December 22, 2023
april@madhedgefundtrader.com

The Future Is Here

Tech Letter

The future is here.

No code or low code will bring a raft of new innovative tech companies to market, and we are in the early innings of this transformative development.

What is no code?

No-code is an approach to designing and using applications that requires zero coding or knowledge of programming languages.

This type of software hits us at a perfect time when the home office is beginning to become ubiquitous.  

The self-service movement that empowers business users will support the creation, manipulation, and employment of data-driven applications.

If we turn back the pages of history, companies need an army of software programmers to develop even the measliest application.

That was then and this is now.

Fast forward to today and automated technology doesn’t only include cutting-edge industries like automotive cars, but also software on laptops that can be rejigged by individual entrepreneurs.

That’s right, one person with no coding experience will be able to design, develop, and offer a real-life application with meaningful business value without the help of expert programmers.

The research data backs up my thesis with research firms projecting a 23% increase in the global market for this type of technology.

During the pandemic, low-code/no-code tools saw steady growth due to their effectiveness in addressing some of tech’s most complicated challenges.

The essential need to digitize workflows and enhance customer and employee experiences will be a boost to the efficiency of commercial and operational teams.

No-code platforms have evolved from just facilitating mundane tasks to making it possible for a broader range of business employees to truly own their automation and build new software applications with no coding while increasing organizational capacity.

A few risks that larger companies might consider is that even for remote developers building new applications, governance is paramount.

IT staff will need to install guardrails in place and have those built into low-code/no-code platforms to maintain consistent levels of security across the organization.

Cybersecurity solutions need to be integrated into this workflow by training every employee at the organization on security behavior and using compartmentalization and limited access to prevent opportunities for mistakes.

Hard landings are hard to recover from and some can be crippling to the business model.

For no-code companies, harmonizing workflows is a key requirement for success.

In a low-code/no-code organization, departments should be able to work without silos and communicate freely across functions.

Elevated performance enabled by low-code/no-code tools will mean that the number of useful apps hurling toward the marketplace will be more and merrier than ever before.

Higher performance will no doubt usher in a new renaissance of efficiency and even better performance.

This also puts a 3 or even 4-day workweek squarely in play.

Many of the best tech minds in the world have supported the concept of working smarter instead of working harder.

A low code/no-code standard will allow for these achievements to take place.

The cratering of costs to start and run a tech firm is affected too.

Deploying startup capital to pay for other expenses will make it easier for successful incubation.

This will ultimately mean that this new type of tech company will need to embrace the fusion of IT and business staff, empowering them with composable applications to speed up the time to market for new solutions.

Low-code/no-code, APIs, and other tools are enabling companies to integrate new applications into their existing tech stack in a more seamless manner with a lift-and-shift approach vs. a rip-and-replace.

At the entrepreneur level, individuals will be able to harness the technology to build $100 million companies with a snap of the fingers when it wasn’t possible to do it before.

This is finally a chance for the little guy to recapture their moxie in the vast and sometimes overwhelming business world.

 

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2023-12-22 14:02:062023-12-22 11:20:24The Future Is Here
Douglas Davenport

THE AI TRIFECTA

Mad Hedge AI

(CRWD), (NVDA), (GOOGL)

Let's talk about the big, the bold, and the brainy world of AI - Artificial Intelligence. Think about the steam engine. The smartphone. They were big, but AI? It's gargantuan, and it's reshaping our world faster than you can say “Siri.”

We're talking about a revolution here – imagine industrial and internet revolutions but with more brains and less steam. So, who are the frontrunners in this AI rat race? Let's dive into the companies that are not simply riding the AI wave, but surfing it like pros.

First up, we have CrowdStrike (CRWD). Data's the new gold, and they are the Fort Knox guards. Their AI-driven security? It's not just good; it's superhero-level good. 

Theft, a tale as old as time, has gone digital. And it's tricky. CrowdStrike's tackling cyber threats like a digital Batman, with AI as its Robin.

As for CrowdStrike's market potential? It's off the charts. From $25 billion in 2019 to a whopping $76 billion. And guess what? It's projected to soar to $158 billion by 2026. Its Falcon platform is a marvel – a blend of AI tools safeguarding data like a fortress.

Despite the economic rollercoaster that 2023 brought us, CrowdStrike's holding strong with a 35% revenue increase to $786 million. And the company’s non-GAAP net income? It doubled to $199 million. 

With ambitions to hit $10 billion in annual recurring revenue, it’s clear that this is one stock that's not just a flash in the pan. Currently valued at 20.2 times sales, CrowdStrike is looking like a pretty sweet deal for the savvy investor.

Next up is Nvidia (NVDA). The big kahuna of GPUs. This tech titan is not offering mere graphics processors. Rather, it is delivering the engines powering advanced AI. Supercomputers, self-driving cars, you name it. Nvidia's GPUs are the muscle behind them. The competition? They're still trying hard to catch up.

Financially, Nvidia is a juggernaut. The company has a revenue of $18.1 billion, indicating a 206% jump. Meanwhile, their data center revenue jumped 279%, and their EPS is at a stunning $3.71, showing off a twelvefold increase. 

Notably, analysts are predicting rainbows and unicorns for Nvidia, with a projected 55% sales increase and a 66% rise in EPS on the horizon. 

Last but definitely not the least, we have Alphabet (GOOG) (GOOGL). You know them, you use them, you probably can’t imagine living without them. 

Google's applications, powered by AI, have become an indispensable part of our daily digital diet. It's where AI meets practicality. From Google Maps to those uncannily accurate news and shopping recommendations, AI is Alphabet's middle name.

As expected, Alphabet's financial muscle is formidable. Apart from an impressive market cap of $1.7 trillion, their annual revenue continues to grow at 11% with their free cash flow CAGR reporting a 28% climb over the last five years. 

For investors, Alphabet's shares have soared 164% in the same period. Taking into consideration the company’s efforts and history, Alphabet isn't just playing when it comes to AI, they're setting the table.

AI is not a passing trend. It's a revolution. A transformative force. From cybersecurity to data analysis, AI is omnipresent. For those seeking to ride this wave, CrowdStrike, Nvidia, and Alphabet are golden tickets.

Remember, change is the heartbeat of AI. These companies aren't simply keeping up; they're leading the charge. Their innovative spirit and strategic AI investments are a siren call to investors ready to dive into the future headfirst. 

So, now, the big question is this: Are you ready to ride the AI wave? Because, trust me, it's going to be one heck of a ride.

https://www.madhedgefundtrader.com/wp-content/uploads/2023/12/12-22-23-1.png 292 512 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2023-12-22 12:52:482023-12-22 12:56:01THE AI TRIFECTA
Page 2 of 12‹1234›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top